[ET Net News Agency, 25 January 2022] UBS lowered its target price for Innovent Bio
(01801) to HK$65 from HK$121.2 and maintained its "buy" rating.
The research house said it likes Innovent Bio for its comprehensive R&D,
commercialisation and execution capabilities. (RC)